has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix ®. Varenicline is used as a smoking cessation product and is available in formats of 0.5 ...

has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix ®. Varenicline is used as a smoking cessation product and is available in formats ...

has launched two new generic prescription drugs. The first product is Varenicline, a generic version of Champix ®. Varenicline is used as a smoking cessation product and is available in formats ...

The course aims to further develop your knowledge, skills and attributes, in line with the requirements of clinical pharmacy practice. Blended learning approach with minimal on campus learning so you ...

the use of pharmaceutical stimulants without a prescription doesn’t reflect use in the general population. In the 2022–23 National Drug Strategy Household Survey, a general population survey ...

Pharmacy teams spend hours each day trying to find medicines affected by availability and pricing issues, says Suraj Shah, drug tariff and reimbursement manager at CPE. In the past year ...

The work resulted in liraglutide, the first long-lasting GLP-1-based drug, approved by the US Food and Drug Administration in 2010 for type 2 diabetes. In the meantime, researchers were already ...

Health care has been invisible for most of the presidential campaign. That changed at last week’s presidential debate, when Donald Trump answered a question about his intentions on the Affordable Care ...

they often walk away without their prescription. “Drug costs ranked higher as a concern for our members than housing costs, and that says a lot in Florida,” said Jeff Johnson, state director ...

to manage their prescription drug benefits. PBMs are essentially middlemen, but they have a huge amount of power because they determine how much pharmacies get compensated for each drug they dispense.

It was released in advance of a United Nations General Assembly meeting later this month on drug-resistant pathogens. “The numbers in the Lancet paper represent a staggering and unacceptable ...